Peptide LexiconAll compounds

Zilucoplan (Zilbrysq): The Daily Macrocyclic Peptide That Blocks Complement C5 in Myasthenia Gravis — What It Is and What Its Trial Showed

Zilucoplan is a 15-amino-acid synthetic macrocyclic peptide that binds complement protein C5. Sold as Zilbrysq, it was FDA-approved in October 2023 as a once-daily self-injection for adults with generalized myasthenia gravis who are anti-acetylcholine-receptor antibody positive, with a boxed warning for meningococcal infection and a restricted-access programme.

FDA-approved (2023)Complement C5 inhibitorMacrocyclic peptide, daily subcutaneous

Caroline S · Published 2026-11-20

Length

15 amino acids, macrocyclic; C172H278N24O55 (free acid), molecular weight 3,562.23 Da (label section 11)

Sequence

Acetylated 15-residue chain with a ring; includes non-standard residues such as N-methyl-aspartate, tert-leucine and 7-azatryptophan, per the label's chemical name

Origin

Synthetic. Zilbrysq, UCB, NDA 216834, original approval 2023-10-17 (Drugs@FDA)

Last reviewed

2026-11-20

What is it good for?

Treating generalized myasthenia gravis in adults whose blood carries antibodies against the acetylcholine receptor. It blocks the last step of the complement cascade, part of the immune system that these antibodies switch on at the junction between nerve and muscle. It is a once-daily injection under the skin from a prefilled syringe.

Illustration: A glass syringe with a copper plunger lying on a white surface beside a deep green shadow.
Illustration

What it is

Zilucoplan is a small synthetic peptide — 15 amino acids, closed into a ring — that blocks complement protein C5. The Zilbrysq label calls it "a 15 amino-acid, synthetic macrocyclic peptide" and gives its free-acid formula as C172H278N24O55 at 3,562.23 daltons. Its chemical name shows that several residues are not among the 20 standard amino acids (N-methyl-aspartate, tert-leucine, 7-azatryptophan); at about 3.6 kDa it is a small molecule by protein standards.

Property Value Source
Length 15 amino acids, macrocyclic Label section 11
Formula (free acid) C172H278N24O55 Label; PubChem CID 133083018
Molecular weight 3,562.23 Da Label
Target Complement C5 Label section 12.1
Route Subcutaneous, once daily, prefilled syringe Label section 2

How it acts. Complement is a chain of blood proteins that, once triggered, ends in a pore-forming complex (C5b-9) that damages cell membranes. In myasthenia gravis, antibodies against the acetylcholine receptor trigger it at the junction where nerve meets muscle. The label states that zilucoplan "binds to the complement protein C5 and inhibits its cleavage to C5a and C5b, preventing the generation of the terminal complement complex, C5b-9" — and, in the same section, that "the precise mechanism by which zilucoplan exerts its therapeutic effect in generalized myasthenia gravis is unknown".

The library's other peptide complement drug acts one step earlier: pegcetacoplan blocks C3.

What the trial showed

The approval rests on one 12-week randomised, double-blind, placebo-controlled trial, RAISE (NCT04115293), described in the label's section 14. It enrolled 174 adults with AChR-antibody-positive generalized myasthenia gravis (MGFA class II–IV, MG-ADL score 6 or more), who kept their existing treatments at stable doses — about 85% were on cholinesterase inhibitors, 63% on steroids and 51% on non-steroidal immunosuppressants. Mean age was 53 and mean time since diagnosis 9 years.

End point at week 12 Zilucoplan (n = 86) Placebo (n = 88) Difference (95% CI)
MG-ADL total score (0–24), change −4.39 −2.30 −2.09 (−3.24 to −0.95), P < 0.001
QMG total score, change −6.19 −3.25 −2.94 (−4.39 to −1.49), P < 0.001
≥3-point MG-ADL improvement 73.1% 46.1% P < 0.001
≥5-point QMG improvement 58% 33% P = 0.0012

The placebo arm improved too — by 2.3 points on a scale where the average starting score was 10.6 — which is why the between-group difference, about two points, is the figure to read.

What is not established by this record: results beyond the 12-week controlled period (the label's safety data note 87 patients exposed for at least a year, not a controlled comparison), use in antibody-negative or MuSK-antibody myasthenia, and any head-to-head comparison with other C5 blockers.

Risks the label lists

Reaction (Study 1) Zilucoplan Placebo
Injection-site reactions 29% 16%
Upper respiratory tract infections 14% 7%
Diarrhoea 11% 2%
Urinary tract infection 8% 5%
Lipase increased 7% 0%
Amylase increased 5% 1%
  • Boxed warning: serious meningococcal infections, which "may become rapidly life-threatening or fatal". The label requires vaccination against serogroups A, C, W, Y and B at least two weeks before the first dose unless delaying treatment is riskier.
  • REMS: Zilbrysq is available only through a restricted programme in which prescribers must enrol and counsel patients about meningococcal risk.
  • Pancreas: pancreatitis and pancreatic cysts have been reported; the label asks for baseline amylase and lipase and for the drug to be stopped while pancreatitis is suspected.

Where it stands

Drugs@FDA lists Zilbrysq under NDA 216834, held by UCB, original approval 17 October 2023, as a prescription solution in three strengths. The label gives a weight-band dose rather than a per-kilogram one: 16.6 mg (under 56 kg), 23 mg (56 to under 77 kg) and 32.4 mg (77 kg and above), each a daily subcutaneous injection — a scheme built around the 0.3 mg/kg dose tested in RAISE. The DailyMed record on 2026-11-20 was version 13, published 5 February 2026.

Sources opened 2026-11-20: Zilbrysq label (openFDA full text, effective 2026-02-03: sections 1, 2, 5, 6 incl. Table 2, 11, 12.1, 14 incl. Table 3); DailyMed SPL listing (version 13, 2026-02-05); Drugs@FDA record for NDA 216834; PubChem CID 133083018; PubMed E-utilities and ClinicalTrials.gov API v2 counts.

What the research shows

Improves daily-living and muscle-strength scores in AChR-antibody-positive generalized myasthenia gravis

RAISE (Study 1, NCT04115293): 174 adults randomised 1:1, 12 weeks; MG-ADL change −4.39 v −2.30 on placebo, difference −2.09 (95% CI −3.24 to −0.95), P < 0.001 (Zilbrysq label, Table 3)

Binds complement C5 and blocks its cleavage

Label section 12.1; the label states the precise mechanism of benefit in myasthenia gravis is unknown

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Prescription drug, NDA 216834 (UCB), approved 2023-10-17; listed as prescription in Drugs@FDA (read 2026-11-20). Boxed warning for serious meningococcal infections; available only through the ZILBRYSQ REMS.

How it is given

Once-daily subcutaneous injection by body weight: 16.6 mg under 56 kg, 23 mg from 56 to under 77 kg, 32.4 mg at 77 kg and above (label section 2.3); about 0.3 mg/kg, the dose studied in RAISE.

Published record

PubMed: 105 records for 'zilucoplan'; ClinicalTrials.gov: 19 studies (2026-11-20). DailyMed label version 13, published 2026-02-05.

Frequently asked questions

What is zilucoplan?

A synthetic ring-shaped peptide of 15 amino acids that blocks complement protein C5. It is sold as Zilbrysq and is approved in the US for adults with generalized myasthenia gravis who have antibodies to the acetylcholine receptor.

How does zilucoplan work?

The label says it binds C5 and stops it being split into C5a and C5b, which prevents the membrane attack complex (C5b-9) from forming. It also says the precise mechanism of benefit in myasthenia gravis is unknown, and is presumed to involve less C5b-9 at the nerve–muscle junction.

What did the main trial show?

In RAISE, 174 adults were randomised to daily zilucoplan or placebo for 12 weeks. The daily-living score (MG-ADL, 0–24) improved by 4.39 points on the drug and 2.30 on placebo, and 73.1% v 46.1% improved by at least 3 points.

What dose does the label state?

One daily injection under the skin, fixed by body weight: 16.6 mg below 56 kg, 23 mg from 56 kg to under 77 kg, and 32.4 mg at 77 kg or more. Each strength has its own plunger colour. Treatment is prescribed by a specialist.

Why is there a boxed warning?

Because blocking complement raises the risk of serious, sometimes fatal infection with Neisseria meningitidis. The label requires meningococcal vaccination at least two weeks before the first dose unless delay is riskier, and the drug is available only through a restricted programme (REMS).

Who was in the trial?

Adults with antibody-positive generalized myasthenia gravis of moderate to severe class, mean age 53, mean 9 years since diagnosis, who stayed on their existing treatments — about 85% on cholinesterase inhibitors, 63% on steroids and 51% on other immunosuppressants.